C4 Therapeutics (CCCC) EBIT Margin (2019 - 2026)
C4 Therapeutics' quarterly EBIT Margin came in at 451.64% in Q1 2026, down 4871.0% year-on-year from 9.47% in Q1 2025, and down 114.96% quarter-over-quarter from 210.1% in Q4 2025.
C4 Therapeutics has reported EBIT Margin for 8 years, with the latest figure at 451.64% in Q1 2026.
- For the quarter ending Q1 2026, EBIT Margin fell 4871.0% year-over-year to 451.64%; the trailing twelve-month figure through Mar 2026 stood at 326.56% (down 3358.0% YoY), and the FY2025 full-year result was 320.53%, up 1561.0% from the prior year.
- EBIT Margin for Q1 2026 stood at 451.64%, down from 210.1% in the prior quarter.
- The five-year high for EBIT Margin was 178.59% in Q2 2024, with the low at 1410.21% in Q2 2023.
- Average EBIT Margin over 5 years is 598.03%, with a median of 440.99% recorded in 2025.
- Year-over-year, EBIT Margin sank 126575 bps in 2022 and surged 123162 bps in 2024.
- Tracing CCCC's EBIT Margin over 5 years: stood at 1341.73% in 2022, then advanced by 14 bps to 1147.72% in 2023, then surged by 37 bps to 728.39% in 2024, then soared by 71 bps to 210.1% in 2025, then plunged by 115 bps to 451.64% in 2026.
- The last three EBIT Margin figures came in at 451.64% (Q1 2026), 210.1% (Q4 2025), and 306.43% (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -6.43% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 38.10% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 17.83% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 23.02% |
| 10 | C4 Therapeutics | 561.03 Mn | 325.36 Mn | - | -451.64% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -451.64% |
| Dec 31, 2025 | -210.10% |
| Sep 30, 2025 | -306.43% |
| Jun 30, 2025 | -440.99% |
| Mar 31, 2025 | -402.93% |
| Dec 31, 2024 | -728.39% |
| Sep 30, 2024 | -183.86% |
| Jun 30, 2024 | -178.59% |
| Mar 31, 2024 | -1,060.18% |
| Dec 31, 2023 | -1,147.72% |
| Sep 30, 2023 | -251.16% |
| Jun 30, 2023 | -1,410.21% |
| Mar 31, 2023 | -963.77% |
| Dec 31, 2022 | -1,341.73% |
| Sep 30, 2022 | -481.02% |
| Jun 30, 2022 | -197.95% |
| Mar 31, 2022 | -409.84% |
| Dec 31, 2021 | -75.98% |
| Sep 30, 2021 | -285.34% |
| Jun 30, 2021 | -226.11% |
| Mar 31, 2021 | -276.18% |
| Dec 31, 2020 | -228.79% |
| Sep 30, 2020 | -217.23% |
| Jun 30, 2020 | -112.30% |
| Mar 31, 2020 | -181.02% |
| Dec 31, 2019 | -127.90% |
| Sep 30, 2019 | -186.45% |